CLINICAL TRIALS PROFILE FOR BREXUCABTAGENE AUTOLEUCEL
✉ Email this page to a colleague
All Clinical Trials for brexucabtagene autoleucel
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02601313 ↗ | Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Active, not recruiting | Kite, A Gilead Company | Phase 2 | 2015-11-09 | The primary objective of the study is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory mantle cell lymphoma (MCL) |
| NCT02614066 ↗ | A Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) | Active, not recruiting | Kite, A Gilead Company | Phase 1/Phase 2 | 2016-03-07 | The primary objectives of this study are to determine the safety and efficacy of brexucabtagene autoleucel (KTE-X19) adult participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). |
| NCT02625480 ↗ | Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Recruiting | Kite, A Gilead Company | Phase 1/Phase 2 | 2016-02-01 | The primary objectives of this study are to evaluate the safety and efficacy of brexucabtagene autoleucel (KTE-X19) in pediatric and adolescent participants with relapsed/refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL). |
| NCT03624036 ↗ | Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Active, not recruiting | Kite, A Gilead Company | Phase 1 | 2018-11-15 | The primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL). |
| NCT03642626 ↗ | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Recruiting | Masonic Cancer Center, University of Minnesota | 2018-12-18 | This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately. | |
| NCT04880434 ↗ | Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) | Recruiting | Kite, A Gilead Company | Phase 2 | 2021-04-27 | The primary objective is to evaluate the efficacy of brexucabtagene autoleucel (KTE-X19) in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL) in Cohort 3 of this study. |
| NCT05495464 ↗ | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | Not yet recruiting | Acerta Pharma, LLC | Early Phase 1 | 2023-01-31 | To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for brexucabtagene autoleucel
Condition Name
Clinical Trial Locations for brexucabtagene autoleucel
Trials by Country
Clinical Trial Progress for brexucabtagene autoleucel
Clinical Trial Phase
Clinical Trial Sponsors for brexucabtagene autoleucel
Sponsor Name
